PRAX vs. AXSM, VKTX, TGTX, KRYS, OGN, SRRK, ALVO, RARE, ADMA, and BHVN
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Axsome Therapeutics (AXSM), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Praxis Precision Medicines vs.
Praxis Precision Medicines (NASDAQ:PRAX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Axsome Therapeutics had 16 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 19 mentions for Axsome Therapeutics and 3 mentions for Praxis Precision Medicines. Axsome Therapeutics' average media sentiment score of 0.76 beat Praxis Precision Medicines' score of 0.39 indicating that Axsome Therapeutics is being referred to more favorably in the news media.
Axsome Therapeutics received 409 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 72.41% of users gave Praxis Precision Medicines an outperform vote while only 69.38% of users gave Axsome Therapeutics an outperform vote.
Axsome Therapeutics has a net margin of -91.87% compared to Praxis Precision Medicines' net margin of -9,409.22%. Praxis Precision Medicines' return on equity of -54.86% beat Axsome Therapeutics' return on equity.
67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Praxis Precision Medicines has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Praxis Precision Medicines has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Praxis Precision Medicines presently has a consensus price target of $146.33, indicating a potential upside of 107.45%. Axsome Therapeutics has a consensus price target of $130.69, indicating a potential upside of 42.17%. Given Praxis Precision Medicines' higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Axsome Therapeutics.
Summary
Axsome Therapeutics beats Praxis Precision Medicines on 11 of the 18 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:PRAX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free PRAX Stock Alerts